#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Implication of cytogenetic and molecular cytogenetic analysis in diagnosis of hematological malignancies in the era of the new sequencing techniques


Authors: Zuzana Zemanová 1;  Kyra Michalová 1;  Jana Březinová 2
Authors‘ workplace: Centrum nádorové cytogenetiky, Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN v Praze 1;  Ústav hematologie a krevní transfuze, Praha 2
Published in: Čas. Lék. čes. 2019; 158: 22-27
Category: Review Article

Overview

In patients with hematological malignancies one of the most substantial findings is the karyotype of bone marrow cells at the time of diagnosis. The detection of clonal chromosome aberrations in diagnostic samples not only confirms a neoplastic or premalignant process but also provides important diagnostic and prognostic information essential for precise disease classification and choice of suitable therapy. Karyotype analysis during the disease course also allows monitoring of the treatment success reflected as well in the revised WHO classification where patients are often classified into the different diagnostic subtypes based on the finding of specific chromosome and/or genetic changes. Recently, also increases the number of advanced treatment approaches that directly or indirectly target the genetic aberrations present in tumor cells. Despite the large development of new sequencing technologies in recent years, cytogenetic analysis supplemented by the molecular cytogenetic methods still remains a very important part of diagnostics of hematological malignancies.

Keywords:

conventional cytogenetic analysis – molecular cytogenetic analysis – karyotype – chromosome aberrations – clonal heterogeneity


Sources
  1. Huret JL (ed.). Atlas of Genetics and Cytogenetics in Oncology and Hematology. Dostupné na: http://AtlasGeneticsOncology.org
  2. Heim S, Mitelman F (eds.). Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells (4th ed.). Wiley-Blackwell, Chichester, 2015.
  3. Swerdlow SH, Campo E, Harris NL et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissue (revised 4th ed.). IARC, Lyon, 2017.
  4. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120(12): 2454–2465.
  5. Bochtler T, Stölzel F, Heilig CHE et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 2013; 31(31): 3898–3905.
  6. MCGOWAN-JORDAN A, SIMONS A, SCHMID M (eds.). ISCN (2016). An international system for human cytogenomic nomenclature. Karger, Basel, 2016.
  7. Michalová K, Zemanová K. Molekulární cytogenetika v diagnostice nádorových onemocnění. Čas Lék Čes 2006; 145: 532–537.
  8. Hastings R, Howell R, Betts D et al. Guidelines and quality assurance for acquired cytogenetics: a common European framework for quality assessment for banded chromosome studies and molecular cytogenetic investigations of acquired abnormalities. E.C.A. Newsletter 2013; 31: 7–21.
  9. Rack KA, van den Berg E, Haferlach C et al. European recommendation and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia 2019 Jan 29, doi: 10.1038/s41375-019-0378-z.
  10. Béné MC, Grimwade D, Haferflach C et al. European LeukemiaNet. Leukemia diagnosis: today and tomorrow. Eur J Haematol 2015; 95(4): 365–373.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#